Benefit-risk assessment of mRNA COVID-19 vaccines in children aged 6 months to 4 years in the Omicron era.

Benefit-risk assessment of mRNA COVID-19 vaccines in children aged 6 months to 4 years in the Omicron era.

Publication date: Jan 17, 2024

There is no risk and benefit assessment of COVID-19 vaccination for children younger than 5 years using a single health outcomes scale. The objective of this study is to compare the expected risk and benefits of the mRNA primary series of COVID-19 vaccines for children aged 6 months to 4 years in the United States using a single health outcome scale in the Omicron era. The expected benefits and risks of primary two-dose series of mRNA COVID-19 vaccines for children aged 6 months to 4 years were stratified by sex, the presence of underlying medical conditions, the presence of infection-induced immunity and the type of mRNA vaccine (BNT162b2 or mRNA-1273). A scoping literature review was conducted to identify the indicators in the decision tree model. The benefit risk ratio was the outcome of interest. The benefit risk ratios ranged from 200. 4 in BNT162b2 for males aged 6-11 months with underlying medical conditions and without infection-induced immunity to 3. 2 in mRNA-1273 for females aged 1-4 years without underlying medical conditions and with infection-induced immunity. The expected benefit of receiving the primary series of mRNA vaccines outweighed the risk among children ages 6 months to 4 years regardless of sex, presence of underlying medical conditions, presence of infection-induced immunity or type of mRNA vaccines. However, the continuous monitoring of the COVID-19 epidemiology as well as vaccine effectiveness and safety is important.

Concepts Keywords
Bnt162b2 children
Females COVID-19
Months quality-adjusted life years
Vaccination risk
safety
vaccine

Semantics

Type Source Name
disease MESH COVID-19
disease VO vaccination
disease VO dose
disease MESH infection
disease VO vaccine
disease VO vaccine effectiveness
disease IDO quality

Original Article

(Visited 1 times, 1 visits today)